XM does not provide services to residents of the United States of America.

Top of the Street: H&M, L'Oreal, EQT, Rheinmetall, Eni, ASMI



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-Top of the Street: H&M, L'Oreal, EQT, Rheinmetall, Eni, ASMI</title></head><body>

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:


** Deutsche Bank double-upgrades H&M HMb.ST to "buy" from "sell", saying it expects structural earnings growth to be higher than the growth potential recognised by the market

** RBC raises L'Oreal OREP.PA to "sector perform" from "underperform", saying the French cosmetics giant has maintained volume growth despite significant price increases and sluggish China

** Deutsche Bank cuts EQT EQTAB.ST to "hold" from "buy", saying it expects a "rather unexciting" Q2 in a still tough fundraising and deal environment, despite a positive medium-term outlook on private markets

** Barclays downgrades British sportswear retailer JD Sports Fashion JD.L to "underweight" from "equal-weight", citing Nike's NKE.N "weak" Q4 and pointing to JD Sports' about 50% revenue exposure to the U.S. sportswear retailer

** Morgan Stanley cuts British multinational private equity and venture capital firm 3i Group III.L to "equal-weight" from "overweight" as it awaits capital market recovery, but says compounding characteristics of 3i-owned discount retailer Action remain compelling


INITIATIONS AND REINSTATEMENTS

** Morgan Stanley initiates Rheinmetall RHMG.DE with "overweight", saying the German arms manufacturer's mid-term growth potential is underappreciated by the market

** Barclays starts coverage of Andritz ANDR.VI with "equal-weight", seeing a mid-single-digit EBITA downside risk for the Austrian industrial equipment maker in FY 2025 and few near-term catalysts for a re-rating

** Barclays also initiates Valmet VALMT.HE with "underweight", warning that the Finnish engineering company's 2025 earnings could be 45% lower than currently expected

** Stifel starts Dutch semiconductor equipment manufacturer ASM International ASMI.AS with "buy", urging investors to maintain a long-term view of its "quasi monopoly" in atomic layer depositioning (ALD) technology, and says it expects the company to continue to deliver

** Morgan Stanley resumes coverage of Eni ENI.MI at "equal-weight", citing the Italian energy group's attractive valuation even if it sees more downside risks to 2024 consensus


(*Analyst rankings from Thomson Reuters StarMine. The scale is from 1-star to 5-star with 5 being the best. Analysts are ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)



Reporting by Olivier Cherfan in Gdansk

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.